Rapport Therapeutics, Inc.(RAPP) - 2025 Q4 - Annual Report

Drug Development and Trials - Company is developing RAP-219, a precision small molecule designed to target TARP8 for treating focal onset seizures (FOS) and other neurological disorders [20]. - Phase 2a trial of RAP-219 in drug-resistant FOS showed statistically significant reduction in long episodes and clinical seizures compared to baseline over an 8-week period [22]. - Company plans to initiate Phase 3 trials for RAP-219 in FOS in Q2 2026 and in primary generalized tonic-clonic seizures (PGTCS) in H1 2027 [22][23]. - RAP-219 is also being evaluated for potential treatment of bipolar mania, with topline results expected in H1 2027 [24]. - Company has initiated IND-enabling activities for RAP-641, a candidate targeting the α6β4 nicotinic acetylcholine receptor for chronic pain and migraine [39]. - The α9α10 nicotinic acetylcholine receptor program is focused on therapies for hearing and vestibular disorders, with small molecule modulators being optimized for clinical advancement [40]. - RAP-219 is advancing to Phase 3 clinical development for Focal Onset Seizures (FOS), with initiation planned for Q2 2026 following FDA meetings [46]. - Following the successful Phase 2a trial, the company plans to initiate two parallel Phase 3 trials of RAP-219 in drug-resistant focal onset seizures in Q2 2026 [102]. - The Phase 3 program will include two trials enrolling over 300 adults each, evaluating RAP-219 over a 14-week treatment period [104]. - The Phase 2a proof-of-concept trial enrolled 30 participants, with 86.7% completing dosing; primary reasons for discontinuation were adverse events [96]. Market Potential and Patient Demographics - The total branded market for epilepsy is projected to grow from approximately $2.8 billion in 2022 to $3.6 billion by 2028 [32]. - Approximately 30 to 40 percent of epilepsy patients experience drug-resistant seizures despite taking two or more antiseizure medications [34]. - Epilepsy affects approximately 50 million people globally, with 3 million adults in the U.S., and the annual direct costs in the U.S. are estimated at $28 billion [54]. - Focal Onset Seizures account for 60% of all epilepsy cases, with an estimated 1.8 million patients in the U.S. affected [61]. - Approximately 0.8 million patients in the U.S. experience Primary Generalized Tonic-Clonic Seizures (PGTCS), representing 25%-35% of all epilepsy patients [105]. - Bipolar disorder affects 2.8% of the adult U.S. population, equating to approximately 7.2 million adults [109]. - The global bipolar disorder market was approximately $1.4 billion in 2022, expected to grow to over $4 billion by 2028 [109]. Drug Efficacy and Safety - RAP-219 demonstrated a half maximal effective concentration (EC50) of 2.3 ng/mL in preclinical models, indicating its potency [70]. - The drug showed no motor impairment in preclinical tests, suggesting a favorable therapeutic index compared to traditional ASMs [70]. - In the Phase 2a trial, 85.2% of patients achieved a ≥30% reduction in long episodes (LEs) from baseline (p<0.0001), and 72.0% achieved a ≥50% reduction in clinical seizures (p<0.0001) [97]. - The median reduction in LE frequency from baseline was 71.0% (p=0.0001), and 24.0% of patients achieved seizure freedom during the 8-week treatment period (p<0.0001) [99]. - The safety profile of RAP-219 was favorable, with the majority of treatment-emergent adverse events (TEAEs) being mild and a low discontinuation rate [100]. - No serious adverse events were reported during the treatment period, with 78.5% of TEAEs being mild and 21.5% moderate [103]. Formulation and Patient Adherence - Company is developing a long-acting injectable formulation of RAP-219 to improve patient adherence, with initial pharmacokinetics results expected in 2027 [27]. - A long-acting injectable (LAI) formulation of RAP-219 is under development, with initial results from a Phase 1 pharmacokinetic study anticipated in 2027 [46]. - The non-adherence rate to prescribed ASMs can be up to approximately 50%, impacting seizure control [112]. Intellectual Property and Licensing - The company owns six patent families directed to TARP8 modulators, with the first patent family expiring in 2036 and covering compositions of matter and methods of use [145]. - The company has a patent family directed to nAChR modulators that expires in 2046, which includes compositions of matter and methods of use [146]. - The company has engaged in a license agreement with Janssen Pharmaceutical NV, which includes a non-refundable upfront payment of $1.0 million and an option fee of $4.0 million for TARP8 products [153]. - Janssen is eligible to receive up to $76.0 million in development milestone payments and up to $40.0 million in sales milestone payments for the lead TARP8 development candidate [153]. - Janssen is eligible to receive royalties ranging from mid to high-single digit percentages on worldwide net sales of TARP8 products [154]. Regulatory Considerations - The FDA aims to review applications for new molecular entities within 10 months and priority review products within 6 months from the date of filing [174]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a product outweigh its risks, which can include special monitoring and patient registries [176]. - The FDA conducts preliminary reviews of New Drug Applications (NDAs) within 60 days to determine completeness before substantive review [174]. - The FDA will not approve an NDA unless manufacturing processes comply with current Good Manufacturing Practices (cGMP) requirements [175]. - Regulatory processes for drug approval require substantial time and financial resources, impacting overall development timelines [158]. - The FDA may impose clinical holds on trials if safety concerns arise, delaying the investigation until issues are resolved [162]. - The FDA has programs like Fast Track, Breakthrough Therapy, and Priority Review to expedite drug development for serious conditions [179]. - Fast Track designation allows for greater interaction with the FDA and rolling review of applications, but the review clock starts only after the final application section is submitted [180]. - Breakthrough Therapy designation indicates substantial improvement over existing therapies, allowing for more senior staff involvement and efficient trial design [181]. - Priority Review can shorten the FDA's review time from 10 months to 6 months for products that significantly improve safety or effectiveness [182]. - Accelerated Approval Pathway allows for earlier approval based on surrogate endpoints, requiring post-approval studies to confirm clinical benefits [183]. - The FDA mandates rigorous post-marketing compliance for products approved under accelerated pathways, including updates every 180 days [186]. Manufacturing and Supply Chain - The company relies on third-party contract manufacturing organizations (CMOs) for all manufacturing needs, with plans to enter into longer-term commercial supply agreements as product candidates advance through clinical development [134]. - The company is developing drug substance and drug product processes for commercial supply, aiming for reliable and cost-effective production [135]. - The company’s competitive factors include efficacy, safety, convenience, price, and the level of generic competition for its product candidates [138]. Market Exclusivity and Patent Regulations - Non-patent exclusivity for new chemical entities (NCE) lasts five years, preventing ANDA submissions until the exclusivity period expires [198]. - Pediatric market exclusivity can add 6 months to existing exclusivity periods if a pediatric study is completed [200]. - NDA sponsors must list all relevant patents with the FDA, which are published in the Orange Book upon approval [201]. - The ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, unless a paragraph IV certification is provided [202]. - A patent claiming a new drug product may be eligible for a patent term extension of up to five years under the Hatch-Waxman Amendments [203]. - Innovative medicinal products approved in the EU qualify for eight years of data exclusivity and an additional two years of market exclusivity [215]. - A marketing authorization in the EU has an initial validity of five years, which can be renewed based on a re-evaluation of the risk-benefit balance [218]. - The centralized procedure for marketing authorization in the EU has a maximum evaluation timeframe of 210 days, which can be reduced to 150 days in exceptional cases [210]. - Orphan designation provides a ten-year market exclusivity period following marketing approval, with specific conditions for granting similar medicinal products [217]. - The Clinical Trials Regulation aims to streamline the approval process for clinical trials in the EU, establishing strict deadlines for application assessments [207]. - A patent term restoration cannot extend beyond a total of 14 years from the product's approval date [203]. - The mutual recognition procedure allows for the acceptance of marketing authorizations between EU Member States [212]. - Pediatric Investigation Plans (PIPs) must be approved before obtaining marketing authorization in the EU, with potential extensions for compliance [213].